Enlivex Therapeutics (NASDAQ:ENLV) Shares Down 2.2%

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) shares fell 2.2% on Friday . The stock traded as low as $1.23 and last traded at $1.36. 82,971 shares traded hands during mid-day trading, a decline of 32% from the average session volume of 122,215 shares. The stock had previously closed at $1.39.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their target price on shares of Enlivex Therapeutics from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, June 11th.

Enlivex Therapeutics Price Performance

The firm’s 50 day moving average price is $1.38 and its two-hundred day moving average price is $2.30.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its quarterly earnings data on Friday, June 14th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. As a group, equities research analysts expect that Enlivex Therapeutics Ltd. will post -0.81 EPS for the current fiscal year.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.